Compare Cenovus Energy Inc (CVE) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs ResMed Inc. — how do they compare? Cenovus Energy Inc trades at $31.25 (market cap $57.90B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: Cenovus Energy Inc is the larger of the two by market cap, and Cenovus Energy Inc pays the higher dividend (1.97%). Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and ResMed Inc. for 51 Days on average.
| CVE | RMD | |
|---|---|---|
Market Cap | $57.90B | $31.89B |
Volume | 7,863,588 | 618,314 |
Sector | Energy | Health |
52-Week High | $33.92 | $277.88 |
52-Week Low | $15.85 | $182.82 |
Typical Hold Time | 46 Days | 51 Days |
Enterprise Value | $63.84B | $31.24B |
Dividend Yield | 1.97% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $30.63, down 1.95% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 12.14, EV/EBITDA of 6.03, and robust profitability metrics including 20.96% ROE. Recent analyst coverage shows 40.74% buy ratings, while technical indicators point to support near $30 with resistance at $31-32 levels. Cash flow trends indicate operational strength with $8.23B from operations in 2025.
CVE presents a mixed outlook with attractive valuation metrics and strong profitability offset by bearish technical signals. The company's projected 2026 revenue growth to $58B and net income of $6.7B suggests upside potential, though energy sector volatility and recent price weakness near key support levels warrant caution. Analyst consensus leans positive with limited sell-side coverage.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
